Disclosure : I currently use compounded tirzepatide through Join Josie (approved at BMI 20 based on menopauserelated symptoms and clinician discretion)
This IPO will fuel progression across its pipeline, offering promising alternatives to injectable GLP-1 therapies
Ongoing communication between patients and healthcare providers is essential to monitor symptom severity, weight changes, glycemic control, and treatment tolerability
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent metabolic disorder that significantly increases the risk of developing cardiovascular disease, type 2 diabetes, chronic kidney disease, liver cirrhosis, and both intra and extrahepatic cancers (110)
When asked in consumer trends research which ingredients they are avoiding, sugar and added sugars ranked number one, followed by salt and sodium, artificial sweeteners, carbohydrates, and saturated fat
Un parche reductor puede contener diversos principios activos, pero ningn anlogo del GLP-1
